Recovering a Regulator-Set Date with Three Acceleration Options
A medical-device manufacturer must complete process validation for a new packaging line before a regulatory submission window that closes in 12 weeks. The submission date is set by the regulator and cannot move. The current critical path has 14 weeks of remaining work. The project manager has three acceleration options. Option A: add a second commissioning shift at $18,000 per week, saving 2 weeks in total before diminishing returns make further shifts ineffective. Option B: run two normally sequential qualification activities in parallel, saving 3 weeks, but engineering assesses a 30% chance of 4 weeks of rework and $90,000 in scrap. Option C: contract a qualified third-party lab for one subsystem at $120,000, saving 4 weeks, though the lab's lead time is uncertain by ±2 weeks. The project has $150,000 remaining in its contingency reserve. The quality director has stated that no validation step may be skipped - only resequenced or resourced.
1. How much compression is required, and what is the expected value of Option B?
Read the worked answer
Minimum compression: 2 weeks. Remaining critical path is 14 weeks against a hard 12-week window. Any plan that does not recover at least 2 weeks fails the submission date, irrespective of cost.
Option B expected value:
- Schedule: 3 weeks saved, but a 30% chance of 4 weeks of rework → 3 − (0.30 × 4) = +1.8 weeks net expected saving.
- Cost: 0.30 × $90,000 = $27,000 expected, plus coordination cost for parallel qualification.
The expected value looks acceptable, but the downside is what matters. If the 30% event fires, the 4-week rework consumes the entire 3-week gain and pushes the project 1 week past the regulator's window. A 30% chance of missing a legislated date is not a risk a governance board should accept when a deterministic alternative exists.
The other two options for comparison:
- A: $18,000 × 2 weeks = $36,000, saves 2 weeks, no schedule uncertainty.
- C: $120,000, saves 4 weeks nominally, worst case 2 weeks (still meets the date), but consumes 80% of the $150,000 contingency.
Note that A alone lands at exactly 12 weeks - on time with zero float. That is a plan, not a buffer.
2. Recommend a combination of options and justify it against the quality director's constraint.
Read the worked answer
Commit A now; pre-qualify C as a trigger; do not commit B.
- Start Option A immediately. It is cheap relative to the alternatives ($36k of a $150k reserve), deterministic, and buys exactly the 2 weeks required. A second shift needs mobilisation time, so each week of delay reduces the weeks of benefit available.
- Avoid B as the primary lever. The expected value is fine, but the tail risk is a missed regulatory window. If parallel running is used at all, apply it to non-critical activities, or require a documented risk acceptance signed by the sponsor and quality director.
- Pre-qualify C without releasing it. Obtain a written lead-time commitment, a fixed price, and a start-date reservation. Hold it as a contingency trigger: if at the end of week 4 the critical path has not recovered to the 8-week mark, release C.
- Address the zero-float problem. A alone leaves no buffer on an immovable date. Ask the sponsor to approve C in advance as a conditional commitment, or to authorise a reserve top-up.
- Respect the quality director's constraint. No step may be skipped, only resequenced or resourced. Any parallel running needs a validation impact assessment showing equivalence, not merely a schedule argument.
Reserve position: A consumes $36k, leaving $114k. Releasing C takes the total to $156k - $6k beyond the contingency - so a triggered C requires sponsor approval against the management reserve.
3. The third-party lab confirms a two-week lead-time slip after contract signature. What is your response and how does the reserve position change?
Read the worked answer
Recompute first.
- C's nominal 4 weeks becomes 2 effective weeks. Combined with A, total recovery is 4 weeks → 10 weeks against a 12-week window, leaving 2 weeks of float. The submission date still holds.
- If C had been chosen as the sole acceleration, the slip would leave the project at exactly 12 weeks with zero float - no better than A alone, at more than three times the cost. That is precisely why A should be committed first and C held as a conditional add-on rather than a substitute.
Commercial response. The ±2-week lead time was a known uncertainty in your own assessment, so this is a realised risk, not a supplier breach. Check whether the contract carries a schedule commitment or liquidated damages; if not, negotiate priority scheduling or a partial deliverable rather than escalating commercially.
Reserve position. $114k remains after A. If C must be re-sequenced or supplemented, the additional cost comes from that balance. If it exceeds the balance, escalate to the sponsor for the management reserve with the consequence stated plainly: pay, or accept a date the regulator will not move.
Register update. Log the realised lead-time risk and its secondary effect on validation documentation, which typically trails lab work and sits on the critical path to submission. Also re-check whether A's second shift can be extended beyond 2 weeks - the earlier assessment said diminishing returns, but the baseline has moved.